To explore the role of SLC25 in antineoplastic drug sensitivity, we utilized GDSC and found that SLC25A5 and SLC25A24, which are highly expressed in colon cancer and indicative of a relatively longer survival time, were associated with the ROCK inhibitor GSK269962A and foretinib sensitivity and tanespimycin, trametinib, and refametinib resistance (Fig. 3E), respectively. Here, SLC25A5 is linked to malignant colon neoplasm.